Dexcom (DXCM) Change in Accured Expenses (2010 - 2026)

Dexcom (DXCM) has reported Change in Accured Expenses for 17 consecutive years, with $112.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 51.75% year-over-year to $112.9 million in Q2 2026; TTM through Jun 2026 was $245.6 million, a 36.9% decrease from a year earlier, with the FY2025 full-year figure at $347.0 million, up 63.91% from the prior year.
• Change in Accured Expenses was $112.9 million for Q2 2026 at Dexcom, down from $145.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $234.0 million in Q2 2025 and troughed at -$30.0 million in Q4 2023.
• A 5-year average of $87.7 million and a median of $81.0 million in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 347.76% in 2023, down 124.23% in 2023.
• Over 5 years, Change in Accured Expenses stood at $123.8 million in 2022, then tumbled by 124.23% to -$30.0 million in 2023, then surged by 33.33% to -$20.0 million in 2024, then surged by 49.5% to -$10.1 million in 2025, then jumped by 1217.82% to $112.9 million in 2026.
• The last three Change in Accured Expenses figures came in at $112.9 million (Q2 2026), $145.1 million (Q1 2026), and -$10.1 million (Q4 2025), per Business Quant data.